Carilex Medical (ROCO:7726) EBIT: NT$-36.9 Mil (TTM As of Dec. 2025)


ROCO:7726 Carilex Medical Inc ROCO:7726
34 GF Score
Price NT$32.45
! 5 Warning Signs
View Full Analysis

What is Carilex Medical EBIT?

Carilex Medical ROCO:7726 +0.15% 34 EBIT is NT$-36.9 Mil as of Dec. 2025. GuruFocus rates ROCO:7726 with a GF Score™ of 34/100. The stock has 5 warning signs investors should review.

Carilex Medical's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was NT$-27.4 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-36.9 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Carilex Medical's annualized ROC % for the quarter that ended in Dec. 2025 was -23.17%. Carilex Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -29.52%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Carilex Medical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -6.08%.

Carilex Medical  (ROCO:7726) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Carilex Medical's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-88.38 * ( 1 - 36.95% )/( (213.122 + 267.959)/ 2 )
=-55.72359/240.5405
=-23.17 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=444.243 - 70.913 - ( 160.208 - max(0, 131.511 - 389.207+160.208))
=213.122

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=533.955 - 55.56 - ( 224.274 - max(0, 221.832 - 432.268+224.274))
=267.959

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Carilex Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-54.812/( ( (23.126 + max(152.016, 0)) + (53.904 + max(142.302, 0)) )/ 2 )
=-54.812/( ( 175.142 + 196.206 )/ 2 )
=-54.812/185.674
=-29.52 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(60.169 + 145.678 + 21.43) - (70.913 + 0 + 4.348)
=152.016

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(88.282 + 95.998 + 23.029) - (55.56 + 0 + 9.447)
=142.302

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Carilex Medical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-36.883/606.735
=-6.08 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carilex Medical EBIT Related Terms

Carilex Medical EBIT Historical Data

* Premium members only.

The historical data trend for Carilex Medical's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carilex Medical EBIT Chart

Carilex Medical Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial 42.88 37.40 58.13 18.23 -36.88

Carilex Medical Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.83 15.86 2.37 -9.48 -27.41

ROCO:7726 vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, Carilex Medical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Carilex Medical EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Carilex Medical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Carilex Medical's EV-to-EBIT falls into.


ROCO:7726
34GF Score
Carilex Medical Inc ROCO:7726
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carilex Medical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-36.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of NT$-36.9 Mil mean?
Carilex Medical (ROCO:7726) has a EBIT of NT$-36.9 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Carilex Medical.
Is Carilex Medical's EBIT too high?
Carilex Medical's current EBIT is NT$-36.9 Mil. Overall, Carilex Medical has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Carilex Medical's EBIT compare to ABT and SYK?
Carilex Medical's EBIT of NT$-36.9 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Carilex Medical. Carilex Medical's current EBIT is NT$-36.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carilex Medical stock overvalued right now?
Carilex Medical (ROCO:7726) has a current EBIT of NT$-36.9 Mil. The current EBIT is NT$-36.9 Mil. Carilex Medical's overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Carilex Medical (ROCO:7726), the current EBIT is NT$-36.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Carilex Medical Business Description

Address No.77, Keji 1st Road, Guishan District, Taoyuan, TWN, 33383
Carilex Medical Inc is a company engaged in the wound care industry by developing leading-edge technology in the prevention and treatment of wounds. Their expertise is in research and development, manufacturing, and quality control and assurance allow us to provide unparalleled products in wound care management in the form of comprehensive product lines proven to prevent and manage pressure sores and wounds. They offer products in the form of Support Surfaces, Chair Cushion and Negative Pressure Wound Therapy.
34GF Score

Get the complete analysis for ROCO:7726

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$32.45
Price